Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Genmab A/S (NASDAQ:GMAB) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Hu...
The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractor...
BTIG analyst Kaveri Pohlman maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $46 to $47.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.
Truist Securities analyst Asthika Goonewardene maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $5...
